Alpha DNA Investment Management Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Becton Dickinson
BDX
|
+$2.17M |
| 2 |
Philip Morris
PM
|
+$1.84M |
| 3 |
Colgate-Palmolive
CL
|
+$1.83M |
| 4 |
RTX Corp
RTX
|
+$1.82M |
| 5 |
Procter & Gamble
PG
|
+$1.81M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$2.5M |
| 2 |
Coca-Cola
KO
|
+$1.81M |
| 3 |
Merck
MRK
|
+$1.72M |
| 4 |
Accenture
ACN
|
+$1.23M |
| 5 |
ExxonMobil
XOM
|
+$1.22M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 13.37% |
| 2 | Healthcare | 12.44% |
| 3 | Financials | 8.73% |
| 4 | Consumer Staples | 6.45% |
| 5 | Industrials | 6% |
Similar funds
Alpha DNA Investment Management's Q3 2023 Portfolio in Review
As of Q3 2023, Alpha DNA Investment Management held 229 positions worth $244M, down 18% from $300M the previous quarter. Its ten largest holdings account for 48% of the portfolio.
Alpha DNA Investment Management withdrew a net $44.9M in Q3 2023, closing 60 positions and reducing 61 holdings. Its most notable exit was Parker-Hannifin, an estimated $1.21M position sold in full.
By sector, the portfolio is most concentrated in Technology at 13% of assets, down from 13% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Alpha DNA Investment Management opened a new position in Becton Dickinson worth $2.07M.
- Alpha DNA Investment Management's largest Q3 2023 buy was Becton Dickinson: 8,016 shares worth $2.07M.
- Alpha DNA Investment Management added most to Microsoft in Q3 2023, an estimated $1.03M increase.
- Alpha DNA Investment Management's biggest Q3 2023 reduction was Visa, cutting an estimated $2.5M.
- Alpha DNA Investment Management fully exited Parker-Hannifin in Q3 2023, selling an estimated $1.21M.
- Alpha DNA Investment Management's ten largest holdings make up 48% of its $244M portfolio in Q3 2023.
- Alpha DNA Investment Management opened 82 new positions and closed 60 in Q3 2023.
- Alpha DNA Investment Management's portfolio value fell 18% quarter-over-quarter to $244M.
Based on Alpha DNA Investment Management's 13F filing for Q3 2023, filed 7 Nov 2023.